| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | aleniglipron Obesity | Phase 2 | 52.5% Aleniglipron, developed by Structure Therapeutics (GPCR), is a once-daily oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1RA) aimed at treating obesity. As a non-peptide mimetic, it provides a pill alternative to established injectable therapies such as Wegovy (semaglutide) and Zepbound (tirzepatide), catering to patient preferences for oral administration amid growing injection fatigue. The obesity market is substantial, projected to reach $150 billion globally by 2030, driven by increasing prevalence and demand for pharmacological interventions. There is a significant unmet need, as current injectable therapies leave approximately 30-40% of patients non-adherent due to needle aversion, while oral options remain limited. Aleniglipron is positioned as a best-in-class oral treatment, claiming "injectable-like efficacy" with a reported 16.3% placebo-adjusted weight loss (39 lbs) at a 180mg dose over 44 weeks, surpassing Lilly's orforglipron, which achieved an 11% weight loss at 72 weeks. Currently, aleniglipron is in the post-Phase 2 development stage, with no further advancements reported as of May 2026. Key trials include ACCESS II (NCT06693843, Phase IIb) and the ACCESS open-label extension (OLE). ACCESS II was a randomized, double-blind, placebo-controlled study involving approximately 85 overweight and obese adults, with the primary endpoint focused on placebo-adjusted weight loss at 44 weeks and secondary endpoints assessing safety and tolerability. The efficacy results were promising, showing weight loss of 16.3% (180mg, p<0.0001), 16.0% (240mg, p<0.0001), and 14.7% (lower dose), with no evidence of a plateau. The OLE demonstrated sustained efficacy, with a continued weight loss of 16.2% (40.5 lbs) at a 120mg dose over 56 weeks. Safety profiles were consistent with the GLP-1 class, with gastrointestinal adverse events (AEs) being predominant, including nausea and vomiting. However, discontinuation rates raised concerns, with an overall rate of 3.4% (median follow-up of 20 weeks), 10.4% in the Phase IIb trial, and 27.9% during titration, which involved a suboptimal 5mg starting dose. No severe cardiac events were reported. Aleniglipron does not currently hold any regulatory designations for obesity, such as Fast Track or Breakthrough Therapy status. The competitive landscape is intense, with approved injectables like semaglutide (15-20% weight loss) and tirzepatide (20-22% weight loss) setting high benchmarks. Orforglipron, an oral competitor with Phase 3 trials completed and imminent approval, shows a weight loss of 11-14%, trailing behind aleniglipron's Phase 2 results but benefiting from a more mature data profile. Other pipeline oral therapies, such as Novo's amycretin, are still lagging in data. The estimated probability of approval (PoA) for aleniglipron stands at 52.5%. This figure reflects strong Phase 2 efficacy, positioning aleniglipron among the top oral therapies with efficacy comparable to injectables, and is supported by consistent results across multiple trials. Historical data suggests a Phase 2-to-approval probability of approximately 45-55% for obesity treatments and GLP-1s. The lack of a plateau in efficacy and relatively low baseline discontinuation rates compared to competitors bolster this PoA, although concerns remain regarding the sponsor's novelty, as Structure Therapeutics has no prior approvals and lacks partnerships with major pharmaceutical companies. The risks include potential increases in adverse events and gaps in long-term efficacy data. Upcoming catalysts include an FDA meeting scheduled for Q2 2026 and the initiation of Phase 3 trials in the second half of 2026. The bullish case suggests that aleniglipron could disrupt the $150 billion obesity market as a best-in-class oral treatment, while the bearish case highlights the risk of eroded differentiation against generics and injectables. This presents a high-reward binary opportunity for GPCR shareholders. Read More | Small Molecules | Endocrine System | ||
Phase 2 data readout example | aleniglipron Obesity | Phase 2 | 52.5% Aleniglipron, developed by Structure Therapeutics (GPCR), is a once-daily oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1RA) aimed at treating obesity. As a non-peptide mimetic, it provides a pill alternative to established injectable therapies such as Wegovy (semaglutide) and Zepbound (tirzepatide), catering to patient preferences for oral administration amid growing injection fatigue. The obesity market is substantial, projected to reach $150 billion globally by 2030, driven by increasing prevalence and demand for pharmacological interventions. There is a significant unmet need, as current injectable therapies leave approximately 30-40% of patients non-adherent due to needle aversion, while oral options remain limited. Aleniglipron is positioned as a best-in-class oral treatment, claiming "injectable-like efficacy" with a reported 16.3% placebo-adjusted weight loss (39 lbs) at a 180mg dose over 44 weeks, surpassing Lilly's orforglipron, which achieved an 11% weight loss at 72 weeks. Currently, aleniglipron is in the post-Phase 2 development stage, with no further advancements reported as of May 2026. Key trials include ACCESS II (NCT06693843, Phase IIb) and the ACCESS open-label extension (OLE). ACCESS II was a randomized, double-blind, placebo-controlled study involving approximately 85 overweight and obese adults, with the primary endpoint focused on placebo-adjusted weight loss at 44 weeks and secondary endpoints assessing safety and tolerability. The efficacy results were promising, showing weight loss of 16.3% (180mg, p<0.0001), 16.0% (240mg, p<0.0001), and 14.7% (lower dose), with no evidence of a plateau. The OLE demonstrated sustained efficacy, with a continued weight loss of 16.2% (40.5 lbs) at a 120mg dose over 56 weeks. Safety profiles were consistent with the GLP-1 class, with gastrointestinal adverse events (AEs) being predominant, including nausea and vomiting. However, discontinuation rates raised concerns, with an overall rate of 3.4% (median follow-up of 20 weeks), 10.4% in the Phase IIb trial, and 27.9% during titration, which involved a suboptimal 5mg starting dose. No severe cardiac events were reported. Aleniglipron does not currently hold any regulatory designations for obesity, such as Fast Track or Breakthrough Therapy status. The competitive landscape is intense, with approved injectables like semaglutide (15-20% weight loss) and tirzepatide (20-22% weight loss) setting high benchmarks. Orforglipron, an oral competitor with Phase 3 trials completed and imminent approval, shows a weight loss of 11-14%, trailing behind aleniglipron's Phase 2 results but benefiting from a more mature data profile. Other pipeline oral therapies, such as Novo's amycretin, are still lagging in data. The estimated probability of approval (PoA) for aleniglipron stands at 52.5%. This figure reflects strong Phase 2 efficacy, positioning aleniglipron among the top oral therapies with efficacy comparable to injectables, and is supported by consistent results across multiple trials. Historical data suggests a Phase 2-to-approval probability of approximately 45-55% for obesity treatments and GLP-1s. The lack of a plateau in efficacy and relatively low baseline discontinuation rates compared to competitors bolster this PoA, although concerns remain regarding the sponsor's novelty, as Structure Therapeutics has no prior approvals and lacks partnerships with major pharmaceutical companies. The risks include potential increases in adverse events and gaps in long-term efficacy data. Upcoming catalysts include an FDA meeting scheduled for Q2 2026 and the initiation of Phase 3 trials in the second half of 2026. The bullish case suggests that aleniglipron could disrupt the $150 billion obesity market as a best-in-class oral treatment, while the bearish case highlights the risk of eroded differentiation against generics and injectables. This presents a high-reward binary opportunity for GPCR shareholders. Read More | Small Molecules | Endocrine System | ||
Phase 2 data readout example | aleniglipron Obesity | Phase 2 | 52.5% Aleniglipron, developed by Structure Therapeutics (GPCR), is a once-daily oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1RA) aimed at treating obesity. As a non-peptide mimetic, it provides a pill alternative to established injectable therapies such as Wegovy (semaglutide) and Zepbound (tirzepatide), catering to patient preferences for oral administration amid growing injection fatigue. The obesity market is substantial, projected to reach $150 billion globally by 2030, driven by increasing prevalence and demand for pharmacological interventions. There is a significant unmet need, as current injectable therapies leave approximately 30-40% of patients non-adherent due to needle aversion, while oral options remain limited. Aleniglipron is positioned as a best-in-class oral treatment, claiming "injectable-like efficacy" with a reported 16.3% placebo-adjusted weight loss (39 lbs) at a 180mg dose over 44 weeks, surpassing Lilly's orforglipron, which achieved an 11% weight loss at 72 weeks. Currently, aleniglipron is in the post-Phase 2 development stage, with no further advancements reported as of May 2026. Key trials include ACCESS II (NCT06693843, Phase IIb) and the ACCESS open-label extension (OLE). ACCESS II was a randomized, double-blind, placebo-controlled study involving approximately 85 overweight and obese adults, with the primary endpoint focused on placebo-adjusted weight loss at 44 weeks and secondary endpoints assessing safety and tolerability. The efficacy results were promising, showing weight loss of 16.3% (180mg, p<0.0001), 16.0% (240mg, p<0.0001), and 14.7% (lower dose), with no evidence of a plateau. The OLE demonstrated sustained efficacy, with a continued weight loss of 16.2% (40.5 lbs) at a 120mg dose over 56 weeks. Safety profiles were consistent with the GLP-1 class, with gastrointestinal adverse events (AEs) being predominant, including nausea and vomiting. However, discontinuation rates raised concerns, with an overall rate of 3.4% (median follow-up of 20 weeks), 10.4% in the Phase IIb trial, and 27.9% during titration, which involved a suboptimal 5mg starting dose. No severe cardiac events were reported. Aleniglipron does not currently hold any regulatory designations for obesity, such as Fast Track or Breakthrough Therapy status. The competitive landscape is intense, with approved injectables like semaglutide (15-20% weight loss) and tirzepatide (20-22% weight loss) setting high benchmarks. Orforglipron, an oral competitor with Phase 3 trials completed and imminent approval, shows a weight loss of 11-14%, trailing behind aleniglipron's Phase 2 results but benefiting from a more mature data profile. Other pipeline oral therapies, such as Novo's amycretin, are still lagging in data. The estimated probability of approval (PoA) for aleniglipron stands at 52.5%. This figure reflects strong Phase 2 efficacy, positioning aleniglipron among the top oral therapies with efficacy comparable to injectables, and is supported by consistent results across multiple trials. Historical data suggests a Phase 2-to-approval probability of approximately 45-55% for obesity treatments and GLP-1s. The lack of a plateau in efficacy and relatively low baseline discontinuation rates compared to competitors bolster this PoA, although concerns remain regarding the sponsor's novelty, as Structure Therapeutics has no prior approvals and lacks partnerships with major pharmaceutical companies. The risks include potential increases in adverse events and gaps in long-term efficacy data. Upcoming catalysts include an FDA meeting scheduled for Q2 2026 and the initiation of Phase 3 trials in the second half of 2026. The bullish case suggests that aleniglipron could disrupt the $150 billion obesity market as a best-in-class oral treatment, while the bearish case highlights the risk of eroded differentiation against generics and injectables. This presents a high-reward binary opportunity for GPCR shareholders. Read More | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
Structure Therapeutics Inc.$36.75
-0.83 (-2.21%)
C 50Pipeline Score Overvalued Pharma · Clinical
Market Cap
2.79 B
EPS
-2.69
P/E Ratio
-
Value Trade
17.64 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
66.51 M
Operating CF
15.23 M
Total Assets
1.51 B
Total Liabilities
61.03 M
Equity
1.45 B
D/E Ratio
12,345
0.46 %
Week
-17.15 %
1 Month
-41.6 %
3 Month
14.12 %
6 Month
56.76 %
5 Year
56.76 %
All Time
Cash Data
Cash Position
1.46 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
343.40 K
52 Week Range
15.80 - 94.90
% held by Insiders
2.33 %
% held by Institutions
89.25 %
Enterprise Value
1.33 B
Total Shares
71.07 M
Short %
8.14 %
Float Shares
69.41 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C50
Pipeline Score $1.4B
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.5x
rNPV / MCap Top 71%
Small Cap (rank 263 of 905)
Percentile RankStructure Therapeutics Inc. carries a moderate pipeline score (50/100), with $2.2B risk-adjusted pipeline value, led by Aleniglipron in Obese (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aleniglipron Small molecule | Obese | Phase 2 | NCT07400588 | 43% | $1.5B | ACTIVE NOT_RECRUITING | 58 | FAST | B (67) | Sep 1, 2026 | MODERATE_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ACCG-2671 | Obesity | Preclinical | 2025-06-23 | |||
ACCG-2671 | Obesity | Preclinical | 2025-06-23 | |||
ACCG-2671 | Obesity | Preclinical | 2025-06-23 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GPCR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV 964.46 M (-31.27%) | Shares Owned 20.02 M (-0.79%) | Activity Avg Price $0 |
|---|---|---|---|---|
Avidity Partners | 0.5 % (-50 %) | 1.99 M | 48.00 K | -88.86% ( -382.90 K) |
Avidity Partners | 0.5 % (-50 %) | 1.99 M | 48.00 K | -88.86% ( -382.90 K) |
Avidity Partners | 0.5 % (-50 %) | 1.99 M | 48.00 K | -88.86% ( -382.90 K) |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
GPCR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GPCR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GPCR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GPCR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
GPCR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 238 | 0 | 238.00 | 2355 | 0 | 0 | 50.87% | 1.14% | 0.99% | - | - | - |
| 2026-07-17 | 238 | 0 | 238.00 | 2355 | 0 | 0 | 50.87% | 1.14% | 0.99% | - | - | - |
| 2026-07-17 | 238 | 0 | 238.00 | 2355 | 0 | 0 | 50.87% | 1.14% | 0.99% | - | - | - |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| 10.5 | 1 | 1 | 27.5 | - | - | 0 |
| 10.5 | 1 | 1 | 27.5 | - | - | 0 |
| 10.5 | 1 | 1 | 27.5 | - | - | 0 |
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Structure Therapeutics Inc. (GPCR) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How GPCR ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Obesity Management | #2 of 3 | Aleniglipron | VKTX BSX ·dev | — | 0.92 |